Table 1.
Baseline Characteristics of WHI Datasets
| WHI-OS Discovery (N=944) |
WHI-HT Validation (N=627) |
|||||
|---|---|---|---|---|---|---|
|
| ||||||
| Cases N = 472 |
Controls N = 472 |
p-value | Cases N = 312 |
Controls N = 315 |
p-value | |
| Age, years | 68 (7) | 67 (7) | 0.51 | 67 (7) | 66 (7) | 0.64 |
|
| ||||||
| Race | 1.00 | 1.00 | ||||
| White | 348 (73%) | 348 (73%) | 254 (81%) | 256 (81%) | ||
| Black | 69 (15%) | 69 (15%) | 37 (12%) | 38 (12%) | ||
| Other | 55 (12%) | 55 (12%) | 21 (7%) | 21 (7%) | ||
|
| ||||||
| Systolic blood pressure, mmHg | 135 (19) | 130 (18) | <0.001 | 137 (19) | 131 (18) | <0.001 |
|
| ||||||
| Diabetes | 78 (17%) | 25 (5%) | <0.001 | 65 (21%) | 31 (10%) | <0.001 |
|
| ||||||
| BMI, m2/kg | 29 (6) | 27 (6) | 0.001 | 30 (6) | 29 (6) | 0.21 |
|
| ||||||
| Total cholesterol, mg/dL | 231 (47) | 232 (47) | 0.51 | 236 (43) | 235 (39) | 0.57 |
|
| ||||||
| HDL cholesterol, mg/dL | 51 (16) | 57 (17) | <0.001 | 47 (12) | 52 (12) | <0.001 |
|
| ||||||
| Smoking status, | 0.016 | 0.033 | ||||
| Current | 48 (10%) | 28 (6%) | 56 (18%) | 34 (11%) | ||
| Former | 209 (44%) | 243 (51%) | 145 (46%) | 166 (53%) | ||
| Never | 215 (46%) | 201 (43%) | 111 (36%) | 115 (36%) | ||
|
| ||||||
| Aspirin use | 116 (25%) | 98 (21%) | 0.16 | 93 (30%) | 78 (25%) | 0.16 |
|
| ||||||
| Statin use | 42 (9%) | 39 (8%) | 0.72 | 60 (19%) | 36 (11%) | 0.007 |
|
| ||||||
| Anti-hypertensive use | 144 (31%) | 91 (19%) | <0.001 | 103 (33%) | 83 (26%) | 0.068 |
|
| ||||||
| Anti-hyperglycemic use | 47 (10%) | 13 (3%) | <0.001 | 52 (17%) | 18 (6%) | <0.001 |
N(%) or mean (SD)